Biocompatibles in deal with BioCure following refocusing
This article was originally published in Clinica
Executive Summary
UK company Biocompatibles has entered into an alliance with US company BioCure, a spin-off of Novartis's CibaVision subsidiary, as an initial step in its new drive to commercialise products for embolisation therapy. Under the deal it will pay BioCure $3m, comprising an up-front payment and approval-based milestones.